Literature DB >> 19563825

Genetic association studies of performance monitoring and learning from feedback: the role of dopamine and serotonin.

Markus Ullsperger1.   

Abstract

Performance monitoring is essential for optimization of action outcomes. Research consistently implicates the posterior medial frontal cortex, particularly the rostral cingulate zone, in monitoring for unfavorable action outcomes, signaling the need for adjustments and learning from feedback. Current theories suggest that phasic dopaminergic signals coding unexpected positive or negative outcomes play a major role in this function. Here, I review EEG, neuroimaging and computational modeling studies making use of polymorphisms of candidate genes affecting neurotransmission, with a specific focus on dopamine. Although the evidence is still rather sparse, findings speak for a prominent role of dopamine in performance monitoring. However, the exact function in cortical areas underlying this function, such as the rostral cingulate zone, remains to be determined. Different hypotheses on the interaction of the rostral cingulate zone, the striatum, and the mesencephalic dopaminergic nuclei are discussed. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563825     DOI: 10.1016/j.neubiorev.2009.06.009

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  14 in total

1.  Dissociation of muscle and cortical response scaling to balance perturbation acceleration.

Authors:  Aiden M Payne; Greg Hajcak; Lena H Ting
Journal:  J Neurophysiol       Date:  2018-12-05       Impact factor: 2.714

Review 2.  Dopamine in motivational control: rewarding, aversive, and alerting.

Authors:  Ethan S Bromberg-Martin; Masayuki Matsumoto; Okihide Hikosaka
Journal:  Neuron       Date:  2010-12-09       Impact factor: 17.173

3.  Potentiated processing of negative feedback in depression is attenuated by anhedonia.

Authors:  Erik M Mueller; Pia Pechtel; Andrew L Cohen; Samuel R Douglas; Diego A Pizzagalli
Journal:  Depress Anxiety       Date:  2015-01-23       Impact factor: 6.505

4.  Disrupted action monitoring in recent-onset psychosis patients with schizophrenia and bipolar disorder.

Authors:  Michael J Minzenberg; Glenn C Gomes; Jong H Yoon; Tamara Y Swaab; Cameron S Carter
Journal:  Psychiatry Res       Date:  2013-11-20       Impact factor: 3.222

Review 5.  Inverted-U-shaped dopamine actions on human working memory and cognitive control.

Authors:  Roshan Cools; Mark D'Esposito
Journal:  Biol Psychiatry       Date:  2011-05-04       Impact factor: 13.382

Review 6.  The roles of dopamine and serotonin in decision making: evidence from pharmacological experiments in humans.

Authors:  Robert D Rogers
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

Review 7.  Neurogenetics and pharmacology of learning, motivation, and cognition.

Authors:  Michael J Frank; John A Fossella
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 8.  Electrophysiological markers of genetic risk for attention deficit hyperactivity disorder.

Authors:  Charlotte Tye; Gráinne McLoughlin; Jonna Kuntsi; Philip Asherson
Journal:  Expert Rev Mol Med       Date:  2011-03-23       Impact factor: 5.600

9.  Genetic polymorphisms of the dopamine and serotonin systems modulate the neurophysiological response to feedback and risk taking in healthy humans.

Authors:  I Heitland; R S Oosting; J M P Baas; S A A Massar; J L Kenemans; K B E Böcker
Journal:  Cogn Affect Behav Neurosci       Date:  2012-12       Impact factor: 3.282

10.  The influence of genetic and environmental factors among MDMA users in cognitive performance.

Authors:  Elisabet Cuyàs; Antonio Verdejo-García; Ana Beatriz Fagundo; Olha Khymenets; Joan Rodríguez; Aida Cuenca; Susana de Sola Llopis; Klaus Langohr; Jordi Peña-Casanova; Marta Torrens; Rocío Martín-Santos; Magí Farré; Rafael de la Torre
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.